OBJECTIVE: Fetal growth restriction (FGR) and small size for gestational age at birth (SGA) are associated with an increased risk of fetal/neonatal mortality. A key element of FGR management is the comparison of expected mortality with expectant management vs. iatrogenic delivery. Further complicating this challenge, maternal hypertensive disorders (chronic hypertension, gestational hypertension, preeclampsia) are often associated with FGR, introducing additional concerns for maternal well-being. Notwithstanding maternal risks, the approach to fetal surveillance is comparable for FGR pregnancies with or without HTN. We sought to determine if neonatal mortality differed in FGR/SGA pregnancies with or without HTN. STUDY DESIGN: We used multivariate logistic regression to compare rates of neonatal death (NND) at specific gestational ages in FGR/ SGA pregnancies with or without maternal HTN. FGR/SGA was defined as a fetal/neonatal weight <10% by Fenton nomogram. In 3 distinct analyses, we compared rates of NND in pregnancies identified at Magee-Womens Hospital from 2000-2015 with FGR by ultrasound (MWH-US; 1,097 FGR, 258 with HTN, 34 NNDs), with SGA birthweight n¼8, 267, 1, 537 HTN, 81 NND) , and all deliveries from 2005-2009 US Vital Statistics with SGA birthweight n¼1, 358, 191, 84, 598 HTN, 11, 427 NND) . RESULTS: NND rates were consistently lower for FGR/SGA neonates born to mothers with HTN than for FGR/SGA neonates without HTN [MWH-US Odds Ratio 0.26 (95% C.I. 0.10, 0.68); MWH-BW OR 0.20 (0.10, 0.37); National-BW OR 0.36 (0.33, 0.39)]. Predicted probabilities of NND with and without HTN at specific gestational ages are shown graphically. CONCLUSION: Gestational-age adjusted NND rates were lower for FGR/SGA pregnancies with HTN than for FGR/SGA pregnancies without HTN. This finding may be attributable to the fact that FGR with HTN is more likely to lead to iatrogenic premature delivery without a fetal indication due to concerns for maternal health. OBJECTIVE: Stillbirth remains unexplained in a significant proportion of fetuses, even after a thorough evaluation. Despite the known contribution of infectious etiologies to this devastating pregnancy outcome, the yield such a workup is of unproven benefit. We aimed to assess the utility of diagnostic tests of maternal and fetal infection in the evaluation of stillbirth. STUDY DESIGN: A single center retrospective study from 1/2011-3/2017 of all women presenting to the hospital with intra-uterine fetal death at or after 20 weeks of gestation. Standard evaluation included a maternal interview, review of medical records, clinical and laboratory inflammatory workup, serology testing (for syphilis, Parvovirus B19, Rubella, CMV, Listeria, Toxoplasmosis, Hepatitis B and C) fetal autopsy, placental pathology and fetal and placental cultures. Additional standard stillbirth workup, including Kleinhauer-Betke, blood for group and screen and HbA1C, was obtained. An infectious etiology was considered the underlying cause of stillbirth if it was supported by at least two diagnostic tests (concordant pathogenic maternal and fetal cultures, histological chorioamnionitis, maternal symptoms of infection or positive serologies) and there was no other probable cause. RESULTS: During the 7-year study period, 228 cases of stillbirth occurred. Placental histological findings diagnostic of overt chorioamnionitis were observed in 69 (30.3%) cases. Serologies of acute infection were positive in 11 (4.8%) of the cases. In 39 cases the placental and abortus cultures were positive for the same pathogen. An infectious etiology was the probable cause of stillbirth, supported by at least two diagnostic tests, in 35 cases (15.3%). The mean gestational age of stillbirth caused by an infection was 29 weeks, while for a non-infectious etiology it was 32 weeks (p¼0.005). 
OBJECTIVE:
To determine the median use of opioid analgesic in the last 24 hours prior to discharge following cesarean delivery and the feasibility of an automated inpatient report to facilitate quantity of opioids indicated for discharge. STUDY DESIGN: Previously, all cesarean deliveries received a set number of opioids at the time of discharge regardless of use while inpatient. In an effort to minimize opioid use while inpatient, a multimodal approach was taken which included the separation of acetaminophen from opioids and scheduling of acetaminophen and non-steroidal anti-inflammatory drugs with opioid use reserved for breakthrough pain. An inpatient report was created which calculated total quantity of 5mg tabs of Roxicodone used in last 24 hours prior to discharge. A 5-day supply of opioids was then prescribed which was individualized based on the last 24-hour intake with a maximum of 40 tabs given. The median, interquartile range, 90 th percentile, and percent of patients requiring zero opioids was determined. RESULTS: There were 129 patients included in this review who underwent a cesarean delivery with a median time from delivery to discharge of 57.7 hours. The median number Roxicodone 5mg tabs given in the last 24 hours prior to discharge was 2 (interquartile range 0 to 4). The 90th percentile was 7 tabs with a maximum of 14. Prior to institution of this quality improvement project, all patients were discharged with 32 tabs of 5mg Roxicodone. After implementation, the median amount was 10 tabs given at discharge with an interquartile range of 0 to 20. Fifty patients (38.8%) required no opioids for last 24 hours prior to discharge. The report was printed daily and made available for obstetric providers to aid in personalizing discharge quantity of opioids. CONCLUSION: With the use of the electronic medical record and automated inpatient narcotic use report, the quantity of opioids at the time of discharge following cesarean delivery can be easily customized with an overall reduction in the amount of opioids dispensed for home use. rd trimester for a longitudinal cohort study, oversampling for women with current/past depression or anxiety. A structured clinical interview was performed at baseline to assess for history or current diagnosis of major depressive or anxiety disorders. Baseline anxiety and depression symptoms were measured using the Beck Depression Inventory (BDI) and the Spielberger Trait Anxiety Inventory (STAI). Mood was measured at baseline and monthly with the Edinburgh Postnatal Depression Scale (EPDS), and at 2, 6, and 12 months postpartum with the BDI, Spielberger State Anxiety Scale, and Parenting Stress Index e Short Form (PSI-SF). Maternal post-traumatic stress disorder (PTSD) symptoms were assessed at 2 months postpartum using the modified Perinatal PTSD Questionnaire (PPQ); birth PTSD was defined using the established threshold of PPQ score 19. We used repeated measures analysis to quantify the association between birth PTSD and postpartum mood and parenting stress through 12 months postpartum, adjusting for prenatal PPD risk and mood symptoms. RESULTS: Data were available from 209 women, of whom 15 (7.2%) had birth PTSD. Compared to women without birth PTSD, these women had higher prenatal STAI-trait (mean 45.1 vs. 33.6, p¼.01) and BDI (mean 18.4 vs. 8.6, p<.01) scores. In repeated measures analysis adjusting for prenatal STAI-Trait score, BDI score and PPD risk status, we found that birth PTSD was independently associated with higher postpartum EPDS (group p¼.03, group x time p¼.01), BDI (group p<.0001), state anxiety (group p¼.002, group x time p¼.01) and PSI-SF (group p¼.002) scores through 12 months postpartum (figure). CONCLUSION: In our sample, 7% of women had birth PTSD. A traumatic birth experience was associated with postpartum anxiety and depression symptoms and parenting stress, independent of prenatal risk. These findings support efforts to minimize traumatic experiences during childbirth, and to provide additional support to women who endorse PTSD symptoms following birth.
